Replies to post #395700 on Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

2023 - No one is buying it.

Because no one knew in 2013 all Brilacidin could do

[loanranger]

"Because no one knew in 2013 all Brilacidin could do."
It's hard for me to believe that others would have bid on brilacidin and the other PYMX IP if they knew that it still wouldn't have generated a marketable drug 10 years later. To the contrary, it's more likely that a concern about that very outcome kept them away.

As you noted I asked this:
"If brilacidin was such a great investment, why didn't anyone else other than Eagle Eye Ehrlich throw money into it?"
No reasonable person would define a great investment as one that generated a loss in share price of 99% in a decade (as this one did).
Your examples didn't do that, did they? And why are you comparing companies with revenues to one that doesn't have any?

"Sentimentality about an asset leads to a lack of discipline."

[xoc]

This is a quote from temple news article below

“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987.

https://news.temple.edu/news/2021-12-14/michael-l-klein-wins-prestigious-john-scott-award